Nelarabine, a water soluble prodrug of 9-b-D-arabinofuranosylguanine (ara-G), is a T-cell specific purine nucleoside analogue. Given its activity in relapsed and refractory T acute lymphoblastic leukemia (T-ALL) and T lymphoblastic lymphoma (T-LBL), we sought to define its role in the frontline treatment of adult patients. Therefore, we conducted a single arm phase 2 study to determine the safety and efficacy of nelarabine in combination with hyper-CVAD in newly diagnosed patients.
| I N TR ODU C TI ON
Historically, the outcome of adult patients with newly diagnosed Tacute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) has been poor with low complete response (CR) rates and short median overall survival (OS) ranging from 11 to 17 months. [1] [2] [3] [4] With the use of intensive chemotherapy regimens, maintenance therapy, and intensive central nervous system (CNS) prophylaxis, CR rates have significantly improved reaching 90% to 95% with long-term diseasefree survival rates of 56% to 65%. [5] [6] [7] [8] [9] Despite this improvement, OS rates have not exceeded 67% with 30% to 40% of the patients relapsing underscoring the need for better therapeutic strategies. [5] [6] [7] [8] Nelarabine, a prodrug of 9-b-D-arabinofuranosylguanine (ara-G), is an ideal T-cell specific purine nucleoside analogue. Upon demethoxylation and intracellular phosphorylation, it is converted to ara-G triphosphate preferentially accumulating in T-lymphoblasts inhibiting DNA 
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replication. [10] [11] [12] [13] Numerous studies have confirmed its antitumor activity in both adult and pediatric patients with relapsed/refractory T-ALL/ LBL leading to its accelerated approval in October 2005 by the Food and Drug Administration for this indication. [14] [15] [16] [17] [18] In this heavily pretreated population, nelarabine induced CR in 31% to 36% of adult patients with a 1-year OS rate ranging from 24% to 28%. 14, 15 Given its activity in relapsed disease, the role of nelarabine combined with intensive chemotherapy in the frontline setting has been of significant interest. In the pediatric experience, newly diagnosed T-ALL patients with slow early response to treatment achieved a 5-year event-free survival of 69% with intensive chemotherapy plus nelarabine identical to that achieved by rapid early responders who did not receive nelarabine. 19 There is limited data on the use of nelarabine in the frontline setting in adult patients. Therefore, we conducted a single-arm phase 2 study to evaluate the safety and efficacy of hyper-CVAD plus nelarabine in the frontline treatment of adult patients with T-ALL/LBL. We previously published preliminary results of this study and here we report an update on the outcome of 67 patients treated at our institution. 20 
| M A TE RI A L S A ND M E TH ODS

| Patient population
Adult patients with previously untreated or minimally pretreated (failure to one induction course or achieving CR after 2 cycles) T-ALL/ LBL were enrolled (NCT00501826 
| Study design and treatment regimen
This is a single-arm phase 2 study designed to determine the efficacy, measured by CR rate, CR duration (CRD), and OS, and safety of adding nelarabine to hyper-CVAD in newly diagnosed patients with T-ALL/ LBL. Therapy consisted of the standard hyper-CVAD regimen as previously described. 5 Figure S1 ). After treating 30 patients, the protocol was amended to introduce nelarabine earlier in induction after cycles four and five, in an attempt to prevent early relapses and improve survival (Supporting Information Figure S1 ).
All patients received CNS prophylaxis consisting of eight intrathecal treatments as previously described. Figure S1 ). Supportive care measures based on standard institutional practice were provided to all patients. 
| Response criteria
| Disease monitoring and immunophenotyping
| Safety assessment
Adverse effects were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0. Guidelines for dose modifications were previously detailed. 5 Nelarabine was dose reduced to 650 mg/m 2 IV on alternate days (1, 3, 5) for patients who develop grade 2 therapy-related neurotoxicity or have grade 1 or 2 neurotoxicity prior to nelarabine courses. Nelarabine was discontinued for grade 3 neurotoxicity except for somnolence, malaise, fatigue, or lethargy that resolve within 24 hours
| Statistical analysis
Differences in the distribution of variables among subgroups were analyzed using x-squared and Mann-Whitney U tests (or Fisher exact tests).
OS was calculated from start of therapy until date of death or last followup. CRD was measured from date of CR until relapse, death, or last follow-up; death in CR was a censored event. OS and CRD curves were plotted using Kaplan-Meier method and compared using the log-rank test. 
| Efficacy and response rates
| Survival
The 3-year probability of CRD and OS for the whole cohort was 66% (95% CI: 52-77) and 65% (95% CI: 51-76), respectively, with a median OS of 82 months ( Figure 1A ,C). There was a nonsignificant statistical improvement in the CRD (69% vs 63%, P 5 .54) and OS (71% vs 62%, P 5 .41) for patients with T-LBL when compared to T-ALL ( Figure 1A ,C).
When analyzed by immunophenotype, no significant differences in CRD or OS were observed among the various subsets ( Figure 1B,D) . Unlike previous reports, presenting WBC count had no impact on OS ( Figure   2A ). 24 Similarly, there was no difference in OS between the two different nelarabine regimens ( Figure 2D ). Patients with complex cytogenetics ( 3 chromosomal abnormalities) had significantly inferior CRD and OS when compared to patients with noncomplex karyotype (Figure 2B ,C).
| Safety and toxicity
Grade 3 nonhematological treatment emergent adverse events were reported in 91% of patients with the most common toxicities including infections (84%), hypokalemia (46%), and hypophosphatemia (40%) (Supporting Information Table S1 ). 
| Comparison with historical hyper-CVAD data
To help us determine the role of nelarabine in the frontline setting, we compared these results to our historical hyper-CVAD data. Newly diag- Abbreviations: T-ALL: T-cell acute lymphoblastic leukemia; T-LBL: T-lymphoblastic lymphoma; ND: not done; IM: insufficient metaphases; BM: bone marrow; CR: complete remission; PR: partial response; mths: months. This group included patients treated with the standard and modified hyper-CVAD regimens. Details regarding these regimens were previously described. 5 We compared both cohorts with regards to baseline characteristics, CRD, and OS (Table 1) . Subset analysis comparing both regimens by diagnosis (T-ALL vs T-LBL) and by immunophenotype (ETP vs Non-ETP) was performed. We found no difference in CRD and OS for the whole cohort with the addition of nelarabine ( Figure 3A,B) . In patients with T-LBL there was a trend toward superior CRD with the use of hyper-CVAD alone which did not translate into an improvement in OS ( Figure 3C,D) . However in T-ALL patients, there was a nonsignificant improvement in the CRD with the combination regimen without an improvement in OS ( Figure 3E,F) . In ETP-ALL/LBL patients, the 3-year OS and CRD was higher using the combination regimen, although these were not statistically significant (P-values, .28 and .67, respectively) ( Figure 3G ,H).
| D I SCUSSION
Hyper-CVAD plus nelarabine is safe and active in the frontline setting with the ability to induce a high CR rate (93%) and durable remissions with no early mortality and a 3-year OS rate of 65%. Earlier administration of nelarabine had no impact on outcome or toxicity. All three patients who developed secondary AML succumbed to the disease indicating the poor prognosis associated with this small subset of patients as previously published by Verma et al. 25 Despite the addition of nelarabine, the relapse rate remained high at 31% similar to previous studies. [5] [6] [7] Outcome of relapsed patients was dismal with 18 deaths (86%) underscoring the need to improve frontline combination regimens.
Intensive chemotherapeutic regimens have significantly improved the outcomes of newly diagnosed adult patients with T-ALL/LBL. [5] [6] [7] [8] In the study conducted by Thomas et al, hyper-CVAD induced CR in 91%
of T-LBL patients with 5-year CRD and OS rates of 62% and 67%, respectively. 5 Comparable results have been reported using the BerlinFrankfurt-Muenster and the UKALL XII/ECOG 2993 protocols. 6, 7, 24 Given the similarity to our results, we compared the combination regimen to our historic hyper-CVAD data and found no difference in OS (65% vs 64%), suggesting no added benefit from the use of nelarabine.
Similar conclusions have been drawn in the relapsed/refractory setting, since the 1-year OS reported with single-agent nelarabine was identical to that reported with multiagent chemotherapeutic regimens (24-28% vs 24%). 14, 15, 26 However, in subset analysis we found a small nonstatistically significant improvement in the CRD (63% vs 50%, P 5 .65) with the combination regimen in patients with T-ALL. Furthermore, patients with ETP ALL/LBL experienced an improvement in OS and CRD from 29% and 25%, in the hyper-CVAD group, to 50% and 56% in the hyper-CVAD plus nelarabine cohort, however the number of patients were too small to achieve statistical significance. Large-scale randomized studies are needed to determine the role of nelarabine in the frontline treatment of higher-risk adult T-ALL/LBL patients.
As previously reported, patients with T-LBL had better outcomes compared to T-ALL. 21, 27, 28 The role of SCT in adult T-ALL remains unclear; with some authors recommending SCT in all patients in CR1
and others restricting SCT to higher-risk patients. Immunophenotype has been found to be the most important prognostic factor for T-ALL with early and mature subtypes associated with the worst OS, 28%
and 29%, respectively. 29 Therefore, in the GMALL studies, SCT in CR1 was recommended to these patients with substantial improvement in the OS of patients within the mature subgroup from 25% without SCT to 59% in transplanted patients suggesting a potential role for SCT in this patient population. 30 However, in a recent study by Jain et al, mature T-ALL/LBL patients treated with intensive chemotherapeutic regimens had a 5-year OS of 70% thereby questioning the role of SCT in these patients. 21 Here, we report similar results with a 3-year OS of 78% for mature T-ALL/LBL patients.
One major limitation of our study was its single-institution, singlearm, nonrandomized design. Our inability to demonstrate a benefit from the addition of nelarabine in standard risk T-ALL/LBL patients may in part be due to potential differences in patient characteristics, small-sized cohorts, nelarabine dosing schedule, and limitations of the historical control analysis. In the relapsed/refractory setting, singleagent nelarabine given at a dose of 1.5 g/m 2 on alternating days in adult patients resulted in CR rates of 31% to 36% compared to 26% in pediatric patients treated at doses ranging from 400 to 900 mg/m 2 daily for five days. [14] [15] [16] This lower response rate was thought to be partly due to the reduced dose schedule used in the pediatric study. 16 Despite being heavily pretreated, the incidence of severe neurotoxicity in relapsed/refractory adult patients was low at 7% to 10%. 14, 15 However, these patients did not receive sequential or concomitant chemotherapy. Since there was no added neurotoxicity upon combining chemotherapy to nelarabine in pediatric studies, we used the pediatric dosing schedule of nelarabine to avoid the potential cumulative neurotoxicity; which may have negatively impacted our results. 16, 19, 31 In conclusion, hyper-CVAD plus nelarabine is safe and active in the frontline setting. Compared to hyper-CVAD alone, there was no survival benefit noted with the addition of nelarabine. The optimal dosing schedule of nelarabine when combined with hyper-CVAD and its role in the treatment of higher-risk patients is yet to be determined. There is an ongoing phase 2 randomized trial (UKALL14) to determine the role of nelarabine, combined with standard induction chemotherapy, in the frontline treatment of adult patients with T-ALL. Novel therapeutic strategies are needed to further improve outcomes of adult T-ALL.
